Episodebeskrivelse
Featuring an interview with Dr Douglas W Sborov, including the following topics:
• DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
• Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
• Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
• Phase I DREAMM-9 trial and ongoing…
Nettsted: hematologic-oncology.captivate.fm

